Elefante Mark B’s Celgene Corp CELG Stock Holding History

Elefante Mark B’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,005	Closed	-$269K	–	45
2018 Q3	$269K	Buy	3,005 +325	+12%	+$28.7K	1.08%	33
2018 Q2	$214K	Buy	+2,680	New	+$223K	1.02%	37

Other funds holding CELG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Elefante Mark B's CELG Position: Q4 2018 in Review

Elefante Mark B sold out of Celgene Corp (CELG) in Q4 2018, closing a stake of 3,005 shares — an estimated $269K sold.

Elefante Mark B first reported a position in CELG in Q2 2018 and held it in 2 quarters. The position peaked at $269K in Q3 2018. 1,317 funds tracked by Wall St. Rank hold CELG as of Q4 2018.

Elefante Mark B reported no remaining Celgene Corp position as of Q4 2018 after selling out during the quarter.
Elefante Mark B sold 3,005 Celgene Corp shares in Q4 2018, an estimated $269K.
Elefante Mark B first reported a position in Celgene Corp in Q2 2018 and held it in 2 quarters.
Elefante Mark B's Celgene Corp position peaked at $269K in Q3 2018.
1,317 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2018.

Based on Elefante Mark B's 13F filing for Q4 2018, filed 24 Jan 2019.